Reports
Reports
Sale
The actinic keratosis treatment market size attained a value of USD 7.40 billion in 2023 driven by environmental factors such as the depletion of ozone and prolonged sun exposure environmental factors such as the depletion of ozone and prolonged sun exposure. The market is anticipated to grow at a CAGR of 4.2% during the forecast period of 2024-2032 to attain a value of USD 10.71 billion by 2032.
Read more about this report - REQUEST FREE SAMPLE COPY IN PDF
The increased prevalence of actinic keratosis, driven by environmental factors such as the depletion of ozone and prolonged sun exposure, is the major factor driving the growth of the actinic keratosis treatment industry globally.
Actinic keratosis refers to the growth of scaly patch on skin that grows out of years of sun exposure. Chances of its occurrence are more in people who are exposed to sunlight, and, thus, are at higher risk of actinic keratosis. The growth of actinic keratosis could lead to squamous cell carcinoma, which is a type of cancer.
Read more about this report - REQUEST FREE SAMPLE COPY IN PDF
The global actinic keratosis treatment industry can be broadly categorised based on segments like therapy, drug class, end-uses, and regions.
The EMR report looks into the regional actinic keratosis treatment markets like North America, Latin America, Europe, the Middle East and Africa, and the Asia Pacific
It is projected that the increasing prevalence of actinic keratosis, the rising acceptance of minimally invasive therapeutic procedures, the availability of appropriate medical coverage, and a growing geriatric population are the major drivers of the market growth. However, the risk factors associated with available treatment options may hamper industry growth over the forecast period.
The hospitals segment, among other end uses, dominates the industry owing to the ease of accessibility, rise in healthcare infrastructure, and the growing number of patients.
Read more about this report - REQUEST FREE SAMPLE COPY IN PDF
The report presents a detailed analysis of the following key players in the global actinic keratosis treatment market, looking into their capacity, market shares, and latest developments like capacity expansions, plant turnarounds, and mergers and acquisitions:
The EMR report gives an in-depth insight into the market by providing a SWOT analysis as well as an analysis of Porter’s Five Forces model.
REPORT FEATURES | DETAILS |
Base Year | 2023 |
Historical Period | 2017-2023 |
Forecast Period | 2024-2032 |
Scope of the Report |
Historical and Forecast Trends, Industry Drivers and Constraints, Historical and Forecast Market Analysis by Segment:
|
Breakup by Treatment Type |
|
Breakup by End User |
|
Breakup by Treatment Channel |
|
Breakup by Distribution Channel |
|
Breakup by Region |
|
Market Dynamics |
|
Supplier Landscape |
|
Companies Covered |
|
*At Expert Market Research, we strive to always give you current and accurate information. The numbers depicted in the description are indicative and may differ from the actual numbers in the final EMR report.
1 Preface
1.1 Objectives of the Study
1.2 Key Assumptions
1.3 Report Coverage – Key Segmentation and Scope
1.4 Research Methodology
2 Executive Summary
3 Actinic Keratosis Diseases Overview
3.1 Guidelines and Stages
3.2 Pathophysiology
3.3 Screening and Diagnosis
3.4 Treatment Pathway
4 Patient Profile
4.1 Patient Profile Overview
4.2 Patient Psychology and Emotional Impact Factors
4.3 Risk Assessment and Treatment Success Rate
5 Actinic Keratosis Epidemiology Analysis
5.1 Epidemiology Overview (2016-2031)
5.2 North America Actinic Keratosis Epidemiology (2016-2031)
5.3 Europe Actinic Keratosis Epidemiology (2016-2031)
5.4 Asia-Pacific Actinic Keratosis Epidemiology (2016-2031)
5.5 Latin America Actinic Keratosis Epidemiology (2016-2031)
5.6 Middle East & Africa Actinic Keratosis Epidemiology (2016-2031)
6 Global Actinic Keratosis Treatment Market Overview
6.1 Global Actinic Keratosis Treatment Market Historical Value (2017-2023)
6.2 Global Actinic Keratosis Treatment Market Forecast Value (2024-2032)
7 Global Actinic Keratosis Treatment Market Landscape
7.1 Global Actinic Keratosis Treatment: Developers Landscape
7.1.1 Analysis by Year of Establishment
7.1.2 Analysis by Company Size
7.1.3 Analysis by Region
7.2 Global Actinic Keratosis Product Landscape
7.2.1 Analysis by Treatment Type
7.2.2 Analysis by End User
7.2.3 Analysis by Distribution Channel
8 Actinic Keratosis Treatment Challenges and Unmet Needs
8.1 Treatment Pathway Challenges
8.2 Compliance and Drop-Out Analysis
8.3 Awareness and Prevention Gaps
9 Cost of Treatment
10 Global Actinic Keratosis Treatment Market Dynamics
10.1 Market Drivers and Constraints
10.2 SWOT Analysis
10.3 Porter’s Five Forces Model
10.4 Key Demand Indicators
10.5 Key Price Indicators
10.6 Industry Events, Initiatives, and Trends
10.7 Value Chain Analysis
11 Global Actinic Keratosis Treatment Market Segmentation
11.1 Global Actinic Keratosis Treatment Market by Treatment Type
11.1.1 Market Overview
11.1.2 Topical Treatments
11.1.2.1 Fluorouracil
11.1.2.2 Imiquimod
11.1.2.3 Diclofenac
11.1.2.4 Ingenol mebutate
11.1.3 Photodynamic Therapy (PDT)
11.1.4 Cryotherapy
11.1.5 Chemical Peels
11.1.6 Laser Therapy
11.1.7 Others
11.2 Global Actinic Keratosis Treatment Market by End User
11.2.1 Market Overview
11.2.2 Hospitals
11.2.3 Dermatology Clinics
11.2.4 Ambulatory Surgical Centers
11.2.5 Homecare
11.2.6 Others (Research Institutes, Academic Institutes, etc.)
11.3 Global Actinic Keratosis Treatment Market by Treatment Channel
11.3.1 Market Overview
11.3.2 Public
11.3.3 Private
11.4 Global Actinic Keratosis Treatment Market by Distribution Channel
11.4.1 Market Overview
11.4.2 Direct Tenders
11.4.3 Retail Sales
11.4.4 Others
11.5 Global Actinic Keratosis Treatment Market by Region
11.5.1 Market Overview
11.5.2 North America
11.5.3 Europe
11.5.4 Asia Pacific
11.5.5 Latin America
11.5.6 Middle East and Africa
12 North America Actinic Keratosis Treatment Market
12.1 Market Share by Country
12.2 United States of America
12.3 Canada
13 Europe Actinic Keratosis Treatment Market
13.1 Market Share by Country
13.2 United Kingdom
13.3 Germany
13.4 France
13.5 Italy
13.6 Others
14 Asia Pacific Actinic Keratosis Treatment Market
14.1 Market Share by Country
14.2 China
14.3 Japan
14.4 India
14.5 ASEAN
14.6 Australia
14.7 Others
15 Latin America Actinic Keratosis Treatment Market
15.1 Market Share by Country
15.2 Brazil
15.3 Argentina
15.4 Mexico
15.5 Others
16 Middle East and Africa Actinic Keratosis Treatment Market
16.1 Market Share by Country
16.2 Saudi Arabia
16.3 United Arab Emirates
16.4 Nigeria
16.5 South Africa
16.6 Others
17 Regulatory Framework
17.1 Regulatory Overview
17.1.1 US FDA
17.1.2 EU EMA
17.1.3 INDIA CDSCO
17.1.4 JAPAN PMDA
17.1.5 Others
18 Patent Analysis
18.1 Analysis by Type of Patent
18.2 Analysis by Publication year
18.3 Analysis by Issuing Authority
18.4 Analysis by Patent Age
18.5 Analysis by CPC Analysis
18.6 Analysis by Patent Valuation
18.7 Analysis by Key Players
19 Grants Analysis
19.1 Analysis by year
19.2 Analysis by Amount Awarded
19.3 Analysis by Issuing Authority
19.4 Analysis by Grant Application
19.5 Analysis by Funding Institute
19.6 Analysis by NIH Departments
19.7 Analysis by Recipient Organization
20 Clinical Trials Analysis
20.1 Analysis by Trial Registration Year
20.2 Analysis by Trial Status
20.3 Analysis by Trial Phase
20.4 Analysis by Therapeutic Area
20.5 Analysis by Geography
21 Funding and Investment Analysis
21.1 Analysis by Funding Instances
21.2 Analysis by Type of Funding
21.3 Analysis by Funding Amount
21.4 Analysis by Leading Players
21.5 Analysis by Leading Investors
21.6 Analysis by Geography
22 Partnership and Collaborations Analysis
22.1 Analysis by Partnership Instances
22.2 Analysis by Type of Partnership
22.3 Analysis by Leading Players
22.4 Analysis by Geography
23 Supplier Landscape
23.1 Galderma S.A.
23.1.1 Financial Analysis
23.1.2 Product Portfolio
23.1.3 Demographic Reach and Achievements
23.1.4 Mergers and Acquisitions
23.1.5 Certifications
23.2 LEO Pharma
23.2.1 Financial Analysis
23.2.2 Product Portfolio
23.2.3 Demographic Reach and Achievements
23.2.4 Mergers and Acquisitions
23.2.5 Certifications
23.3 Bausch Health Companies Inc.
23.3.1 Financial Analysis
23.3.2 Product Portfolio
23.3.3 Demographic Reach and Achievements
23.3.4 Mergers and Acquisitions
23.3.5 Certifications
23.4 Almirall, S.A.
23.4.1 Financial Analysis
23.4.2 Product Portfolio
23.4.3 Demographic Reach and Achievements
23.4.4 Mergers and Acquisitions
23.4.5 Certifications
23.5 Sun Pharmaceutical Industries Ltd.
23.5.1 Financial Analysis
23.5.2 Product Portfolio
23.5.3 Demographic Reach and Achievements
23.5.4 Mergers and Acquisitions
23.5.5 Certifications
23.6 Perrigo Company plc.
23.6.1 Financial Analysis
23.6.2 Product Portfolio
23.6.3 Demographic Reach and Achievements
23.6.4 Mergers and Acquisitions
23.6.5 Certifications
23.7 GlaxoSmithKline plc.
23.7.1 Financial Analysis
23.7.2 Product Portfolio
23.7.3 Demographic Reach and Achievements
23.7.4 Mergers and Acquisitions
23.7.5 Certifications
23.8 Novartis AG
23.8.1 Financial Analysis
23.8.2 Product Portfolio
23.8.3 Demographic Reach and Achievements
23.8.4 Mergers and Acquisitions
23.8.5 Certifications
23.9 Valeant Pharmaceuticals International, Inc.
23.9.1 Financial Analysis
23.9.2 Product Portfolio
23.9.3 Demographic Reach and Achievements
23.9.4 Mergers and Acquisitions
23.9.5 Certifications
23.10 Teva Pharmaceutical Industries Ltd.
23.10.1 Financial Analysis
23.10.2 Product Portfolio
23.10.3 Demographic Reach and Achievements
23.10.4 Mergers and Acquisitions
23.10.5 Certifications
24 Actinic Keratosis Treatment Market- Distribution Model (Additional Insight)
24.1 Overview
24.2 Potential Distributors
24.3 Key Parameters for Distribution Partner Assessment
25 Key Opinion Leaders (KOL) Insights (Additional Insight)
26 Company Competitiveness Analysis (Additional Insight)
26.1 Very Small Companies
26.2 Small Companies
26.3 Mid-Sized Companies
26.4 Large Companies
26.5 Very Large Companies
27 Payment Methods (Additional Insight)
27.1 Government Funded
27.2 Private Insurance
27.3 Out-of-Pocket
*Additional insights provided are customisable as per client requirements.
In 2023, the global market for actinic keratosis reached a value of USD 7.40 billion.
The market is anticipated to grow at a CAGR of 4.2% during the forecast period of 2024-2032 to reach a value of USD 10.71 billion by 2032.
The major drivers of the market include the increasing prevalence of actinic keratosis, growing acceptance of minimally invasive therapeutic procedures, and increasing geriatric population.
Depletion of ozone layer leading to an increased incidence of actinic keratosis is the key industry trend propelling the growth of the market.
The major regions in the industry are North America, Latin America, the Middle East and Africa, Europe, and the Asia Pacific.
The leading therapies of actinic keratosis treatment in the market are topical, surgery, and photodynamic therapy.
The major drug classes of actinic keratosis treatment in the industry are nucleoside metabolic inhibitors, nonsteroidal anti-inflammatory drugs, immune response modifiers, and photoenhancers, among others.
The significant end use sectors of actinic keratosis treatment in the market are hospitals, private clinics, and homecare, among others.
The major players in the industry are Bausch Health Companies Inc., LEO Pharma A/S, Almirall, S.A., Biofrontera, and Hill Dermaceuticals Inc., among others.
Mini Report
Single User License
Five User License
Corporate License
Any Question? Speak With An Analyst
View A Sample
Did You Miss Anything, Ask Now
Right People
We are technically excellent, strategic, practical, experienced and efficient; our analysts are hand-picked based on having the right attributes to work successfully and execute projects based on your expectations.
Right Methodology
We leverage our cutting-edge technology, our access to trusted databases, and our knowledge of the current models used in the market to deliver you research solutions that are tailored to your needs and put you ahead of the curve.
Right Price
We deliver in-depth and superior quality research in prices that are reasonable, unmatchable, and shows our understanding of your resource structure. We, additionally, offer attractive discounts on our upcoming reports.
Right Support
Our team of expert analysts are at your beck and call to deliver you optimum results that are customised to meet your precise needs within the specified timeframe and help you form a better understanding of the industry.